• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

NITD-349

CAS No. 1473450-62-2

NITD-349 ( NITD349 )

产品货号. M12026 CAS No. 1473450-62-2

NITD-349 是一种新型口服生物可利用的分枝杆菌膜蛋白大 3 (MmpL3) 抑制剂,针对结核分枝杆菌 H37Rv 的 MIC 为 23 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥365 有现货
5MG ¥583 有现货
10MG ¥988 有现货
25MG ¥1798 有现货
50MG ¥3013 有现货
100MG ¥4504 有现货
500MG ¥9882 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    NITD-349
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    NITD-349 是一种新型口服生物可利用的分枝杆菌膜蛋白大 3 (MmpL3) 抑制剂,针对结核分枝杆菌 H37Rv 的 MIC 为 23 nM。
  • 产品描述
    NITD-349 is a novel, orally bioavailable mycobacterial membrane protein Large 3 (MmpL3) inhibitor with MIC of 23 nM against M tuberculosis H37Rv; shows potent activity against both drug-sensitive and multidrug-resistant clinical isolates of Mtb; demonstrates effectivity in treating both acute and chronic Mtb infections in mouse efficacy models.
  • 体外实验
    NITD-349 shows bactericidal activity against in vitro replicating Mycobacterium tuberculosis (Mtb) and also are active against intramacrophage Mtb. Kill kinetic analysis of these compounds showed both concentration- and time-dependent killing of Mtb cells with 3- to 4-log colony-forming unit (CFU) reductionwithin 3 days of treatment. The cidal activity profile of NITD-304 is similar to that of isoniazid for which rapid killing is noticed at concentrations greater than 0.2 μM. The MIC activity of NITD349 against various MDR Mtb strains ranges from 0.04 to 0.08 μM. NITD-349 shows high permeability and moderate in vitro metabolic clearance in mouse and human hepatic microsomes.
  • 体内实验
    In the acute murine efficacy modelNITD-349 shows favorable oral pharmacokinetic (PK) properties in rodents and dogs and are efficacious in mouse models of both acute and chronic Mycobacterium tuberculosis infection. In the acute murine efficacy model, treatment of mice with NITD-349 at doses of 12.5 and 50 mg/kg resulted in 0.9- and 3.4-log CFU reduction in lung tissue. In an established infection mouse model, after 2 weeks of treatment, the efficacy of NITD-349 is comparable to the first-line TB drug rifampicin and is better than ethambutol. Four weeks of treatment at 100 mg/kg with NITD-349 results in 2.38-log CFU reductions.
  • 同义词
    NITD349
  • 通路
    GPCR/G Protein
  • 靶点
    Antibacterial
  • 受体
    Antibacterial
  • 研究领域
    Infection
  • 适应症
    ——

化学信息

  • CAS Number
    1473450-62-2
  • 分子量
    306.36
  • 分子式
    C17H20F2N2O
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : ≥ 310 mg/mL 1011.91 mM
  • SMILES
    CC1(CCC(CC1)NC(=O)C2=CC3=C(N2)C=C(C=C3F)F)C
  • 化学全称
    N-(4,4-dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Rao SP, et al. Sci Transl Med. 2013 Dec 4;5(214):214ra168.
产品手册
关联产品
  • Ribocil-C

    一种 FMN 核糖开关的高度选择性抑制剂,可控制大肠杆菌中核黄素(维生素 B2)从头生物合成的表达。

  • Vitexin -4''-O-gluco...

    Vitexin-4''-O-glucoside 可通过恢复线粒体功能,有效保护 ECV-304 细胞免受 TBHP 诱导的细胞毒性。

  • β-Glucuronidase-IN-1

    β-Glucuronidase-IN-1 是强效的,选择性,非竞争性和具有口服活性的 E. coli β-葡萄糖醛酸酶 (β-glucuronidase) 抑制剂,针对 E. coli β-葡萄糖醛酸酶的 IC50 和 Ki 值分别为 283 nM 和 164 nM。